TY - JOUR
T1 - Financial incentives and physicians' prescription decisions on the choice between brand-name and generic drugs
T2 - Evidence from Taiwan
AU - Liu, Ya Ming
AU - Yang, Yea Huei Kao
AU - Hsieh, Chee Ruey
N1 - Funding Information:
We would like to thank Tetsuji Yamada and two anonymous referees for helpful suggestions. Financial support from the National Science Council (NSC95-2415-H-006-006) and the Department of Health (DOH96-TD-D-113-026) in Taiwan is gratefully acknowledged.
PY - 2009/3
Y1 - 2009/3
N2 - This paper tests the hypothesis of whether or not financial incentives affect a physician's prescription decision on the choice of generic versus brand-name drugs within a system in which physicians prescribe and dispense drugs. By using data obtained from Taiwan and focusing on diabetic patients, our empirical results provide several consistent findings in support of the hypothesis that profit incentives do affect the physician's prescribing decision, suggesting that physicians act as imperfect agents. An important implication of our findings is that rent seeking for profit margin between the reimbursement and the acquisition price instead of reducing costs is the major driving force behind generic substitution. As a result, the providers instead of the payers or consumers reap the financial benefits of generic substitution.
AB - This paper tests the hypothesis of whether or not financial incentives affect a physician's prescription decision on the choice of generic versus brand-name drugs within a system in which physicians prescribe and dispense drugs. By using data obtained from Taiwan and focusing on diabetic patients, our empirical results provide several consistent findings in support of the hypothesis that profit incentives do affect the physician's prescribing decision, suggesting that physicians act as imperfect agents. An important implication of our findings is that rent seeking for profit margin between the reimbursement and the acquisition price instead of reducing costs is the major driving force behind generic substitution. As a result, the providers instead of the payers or consumers reap the financial benefits of generic substitution.
UR - http://www.scopus.com/inward/record.url?scp=62049084257&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=62049084257&partnerID=8YFLogxK
U2 - 10.1016/j.jhealeco.2008.10.009
DO - 10.1016/j.jhealeco.2008.10.009
M3 - Article
C2 - 19091433
AN - SCOPUS:62049084257
SN - 0167-6296
VL - 28
SP - 341
EP - 349
JO - Journal of Health Economics
JF - Journal of Health Economics
IS - 2
ER -